
FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.
Hovione's plant in Portugal has successfully passed its twelfth FDA inspection in 18 months.
Hovione’s five plants were the object of 12 inspections in the last 18 months. These inspections were performed by health authorities, including five by FDA, three by the Portuguese Health Authority, one by the Irish Medicines Board, one by Korean health authorities, and two by China’s health authority.
Source:





